The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains
Open accessAbstract
Small-molecule inhibitors that target bromodomains outside of the bromodomain and extra-terminal (BET) sub-family are lacking. Here, we describe highly potent and selective ligands for the bromodomain module of the human lysine acetyl transferase CBP/p300, developed from a series of 5-isoxazolyl-benzimidazoles. Our starting point was a fragment hit, which was optimized into a more potent and selective lead using parallel synthesis employing Suzuki couplings, benzimidazole-forming reactions, and reductive aminations. The selectivity of the lead compound against other bromodomain family members was investigated using a thermal stability assay, which revealed some inhibition of the structurally related BET family members. To address the BET selectivity issue, X-ray crystal structures of the lead compound bound to the CREB binding protein (CBP) and the first bromodomain of BRD4 (BRD4(1)) were used to guide the design of more selective compounds. The crystal structures obtained revealed two distinct binding modes. By varying the aryl substitution pattern and developing conformationally constrained analogues, selectivity for CBP over BRD4(1) was increased. The optimized compound is highly potent (Kd = 21 nM) and selective, displaying 40-fold selectivity over BRD4(1). Cellular activity was demonstrated using fluorescence recovery after photo-bleaching (FRAP) and a p53 reporter assay. The optimized compounds are cell-active and have nanomolar affinity for CBP/p300; therefore, they should be useful in studies investigating the biological roles of CBP and p300 and to validate the CBP and p300 bromodomains as therapeutic targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Self-citationThe Transcriptional Coactivators p300 and CBP Are Histone Acetyltransferases
Ogryzko, V. V., Schiltz, R. L., Russanova, V., Howard, B. H., & Nakatani, Y. (1996) · Cell · doi:10.1016/s0092-8674(00)82001-2 · Cited by 2,952
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
Ligand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
The CBP co-activator is a histone acetyltransferase
Bannister, A. J., & Kouzarides, T. (1996) · Nature · doi:10.1038/384641a0 · Cited by 1,805
CBP/p300 in cell growth, transformation, and development
Goodman, R. H., & Smolik, S. (2000) · Genes & Development · doi:10.1101/gad.14.13.1553 · Cited by 1,778
Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
Filippakopoulos, P., Picaud, S., Mangos, M., Keates, T., Lambert, J.-P., Barsyte-Lovejoy, D., Felletar, I., Volkmer, R., Müller, S., Pawson, T., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.013 · Cited by 1,694
Self-citationSuppression of inflammation by a synthetic histone mimic
Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.-W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010) · Nature · doi:10.1038/nature09589 · Cited by 1,563
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.-I., Robson, S. C., Chung, C.-W., Hopf, C., Savitski, M. M., et al. (2011) · Nature · doi:10.1038/nature10509 · Cited by 1,503
DNA damage activates p53 through a phosphorylation–acetylation cascade
Sakaguchi, K., Herrera, J. E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C. W., & Appella, E. (1998) · Genes & Development · doi:10.1101/gad.12.18.2831 · Cited by 1,204
p300/CBP proteins: HATs for transcriptional bridges and scaffolds
Chan, H. M., & La Thangue, N. B. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.13.2363 · Cited by 1,092
CREB-binding Protein and p300 in Transcriptional Regulation
Vo, N., & Goodman, R. H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.r000025200 · Cited by 866
An essential role for p300/CBP in the cellular response to hypoxia
Arany, Z., Huang, L. E., Eckner, R., Bhattacharya, S., Jiang, C., Goldberg, M. A., Bunn, H. F., & Livingston, D. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.23.12969 · Cited by 790
p53 Sites Acetylated In Vitro by PCAF and p300 Are Acetylated In Vivo in Response to DNA Damage
Liu, L., Scolnick, D. M., Trievel, R. C., Zhang, H. B., Marmorstein, R., Halazonetis, T. D., & Berger, S. L. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1202 · Cited by 776
Bromodomain: an acetyl‐lysine binding domain
Zeng, L., & Zhou, M.-M. (2002) · FEBS Letters · doi:10.1016/s0014-5793(01)03309-9 · Cited by 746
Recruitment of p300/CBP in p53-Dependent Signal Pathways
Avantaggiati, M. L., Ogryzko, V., Gardner, K., Giordano, A., Levine, A. S., & Kelly, K. (1997) · Cell · doi:10.1016/s0092-8674(00)80304-9 · Cited by 669
Kallio, P. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.22.6573 · Cited by 666
Ema, M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.7.1905 · Cited by 587
Suppression of tumor growth through disruption of hypoxia-inducible transcription
Kung, A. L., Wang, S., Klco, J. M., Kaelin, W. G., & Livingston, D. M. (2000) · Nature Medicine · doi:10.1038/82146 · Cited by 501
CBP and p300: HATs for different occasions
Kalkhoven, E. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.03.045 · Cited by 496
French, C. A., Ramirez, C. L., Kolmakova, J., Hickman, T. T., Cameron, M. J., Thyne, M. E., Kutok, J. L., Toretsky, J. A., Tadavarthy, A. K., Kees, U. R., et al. (2008) · Oncogene · doi:10.1038/sj.onc.1210852 · Cited by 441
Carrero, P., Okamoto, K., Coumailleau, P., O'Brien, S., Tanaka, H., & Poellinger, L. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.1.402-415.2000 · Cited by 385
The bromodomain interaction module
Filippakopoulos, P., & Knapp, S. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.04.045 · Cited by 374
Self-citationStructural Mechanism of the Bromodomain of the Coactivator CBP in p53 Transcriptional Activation
Mujtaba, S., He, Y., Zeng, L., Yan, S., Plotnikova, O., Sachchidanand, Sanchez, R., Zeleznik-Le, N. J., Ronai, Z., & Zhou, M.-M. (2004) · Molecular Cell · doi:10.1016/s1097-2765(03)00528-8 · Cited by 319
Mirguet, O., Gosmini, R., Toum, J., Clément, C. A., Barnathan, M., Brusq, J.-M., Mordaunt, J. E., Grimes, R. M., Crowe, M., Pineau, O., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401088k · Cited by 305
Structure of the p300 catalytic core and implications for chromatin targeting and HAT regulation
Delvecchio, M., Gaucher, J., Aguilar-Gurrieri, C., Ortega, E., & Panne, D. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2642 · Cited by 303
The role of human bromodomains in chromatin biology and gene transcription.
Sánchez, R., & Zhou, M. (2009) · PubMed · Cited by 298
Bedford, D. C., Kasper, L. H., Fukuyama, T., & Brindle, P. K. (2010) · Epigenetics · doi:10.4161/epi.5.1.10449 · Cited by 292
Ebert, B. L., & Bunn, H. F. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.4089 · Cited by 282
Druggability Analysis and Structural Classification of Bromodomain Acetyl-lysine Binding Sites
Vidler, L. R., Brown, N., Knapp, S., & Hoelder, S. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300346w · Cited by 278
Self-citationRyckmans, T., Edwards, M. P., Horne, V. A., Correia, A. M., Owen, D. R., Thompson, L. R., Tran, I., Tutt, M. F., & Young, T. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.05.062 · Cited by 270
p300/CBP/p53 interaction and regulation of the p53 response
Grossman, S. R. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.02226.x · Cited by 263
p53-Mdm2--the affair that never ends
Alarcon-Vargas, D. (2002) · Carcinogenesis · doi:10.1093/carcin/23.4.541 · Cited by 233
3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands
Hewings, D. S., Wang, M., Philpott, M., Fedorov, O., Uttarkar, S., Filippakopoulos, P., Picaud, S., Vuppusetty, C., Marsden, B., Knapp, S., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200640v · Cited by 216
Self-citationp53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism
Duan, W., Zhu, X., Ladenheim, B., Yu, Q., Guo, Z., Oyler, J., Cutler, R. G., Cadet, J. L., Greig, N. H., & Mattson, M. P. (2002) · Annals of Neurology · doi:10.1002/ana.10350 · Cited by 204
Fish, P. V., Filippakopoulos, P., Bish, G., Brennan, P. E., Bunnage, M. E., Cook, A. S., Federov, O., Gerstenberger, B. S., Jones, H., Knapp, S., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3010515 · Cited by 198
Self-citationPlace your BETs: the therapeutic potential of bromodomains
Prinjha, R. K., Witherington, J., & Lee, K. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.12.002 · Cited by 197
Shultz, M. D. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.08.029 · Cited by 175
Bamborough, P., Diallo, H., Goodacre, J. D., Gordon, L., Lewis, A., Seal, J. T., Wilson, D. M., Woodrow, M. D., & Chung, C.-W. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201283q · Cited by 175
Zeng, L., Zhang, Q., Gerona‐Navarro, G., Moshkina, N., & Zhou, M. (2008) · Structure · doi:10.1016/j.str.2008.01.010 · Cited by 154
Lamoureux, F., Baud’huin, M., Calleja, L. R., Jacques, C., Berreur, M., Rédiní, F., Lecanda, F., Bradner, J. E., Heymann, D., & Ory, B. (2014) · Nature Communications · doi:10.1038/ncomms4511 · Cited by 151
Sachchidanand, Resnick‐Silverman, L., Yan, S. X., Mutjaba, S., Liu, W., Zeng, L., Manfredi, J. J., & Zhou, M. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.10.014 · Cited by 145
Prospective therapeutic applications of p53 inhibitors
Gudkov, A. V., & Komarova, E. A. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.153 · Cited by 142
Optimization of 3,5-Dimethylisoxazole Derivatives as Potent Bromodomain Ligands
Hewings, D. S., Fedorov, O., Filippakopoulos, P., Martin, S., Picaud, S., Tumber, A., Wells, C. D., Olcina, M. M., Freeman, K. M., Gill, A., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301588r · Cited by 141
Self-citationBromodomain-peptide displacement assays for interactome mapping and inhibitor discovery
Philpott, M., Yang, J., Tumber, T., Fedorov, O., Uttarkar, S., Filippakopoulos, P., Picaud, S., Keates, T., Felletár, I., Ciulli, A., et al. (2011) · Molecular BioSystems · doi:10.1039/c1mb05099k · Cited by 141
Self-citationA Small Molecule Binding to the Coactivator CREB-Binding Protein Blocks Apoptosis in Cardiomyocytes
Borah, J. C., Mujtaba, S., Karakikes, I., Zeng, L., Müller, M., Patel, J. A., Moshkina, N., Morohashi, K., Zhang, W., Gerona‐Navarro, G., et al. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.12.021 · Cited by 136
Open access chemical and clinical probes to support drug discovery
Edwards, A. M., Bountra, C., Kerr, R. S., & Willson, T. M. (2009) · Nature Chemical Biology · doi:10.1038/nchembio0709-436 · Cited by 130
Rooney, T. P. C., Filippakopoulos, P., Fedorov, O., Picaud, S., Cortopassi, W. A., Hay, D. A., Martin, S., Tumber, A., Rogers, C. M., Philpott, M., et al. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201402750 · Cited by 119
Self-citationp53-mediated neuronal cell death in ischemic brain injury
Hong, L.-Z., Zhao, X.-Y., & Zhang, H.-L. (2010) · Neuroscience Bulletin · doi:10.1007/s12264-010-1111-0 · Cited by 100
[1,2,4]Triazolo[4,3-a]phthalazines: Inhibitors of Diverse Bromodomains
Fedorov, O., Lingard, H., Wells, C. D., Monteiro, O., Picaud, S., Keates, T., Yapp, C., Philpott, M., Martin, S. J., Felletár, I., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401568s · Cited by 99
Self-citationHelen, S., Horne, G. A., Bastow, S., & Chevassut, T. J. T. (2013) · Cancer Medicine · doi:10.1002/cam4.146 · Cited by 91
The p53 response: Emerging levels of co-factor complexity
Coutts, A. S., & La Thangue, N. B. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.150 · Cited by 72
Hay, D. A., Fedorov, O., Filippakopoulos, P., Martin, S., Philpott, M., Picaud, S., Hewings, D. S., Uttakar, S., Heightman, T. D., Conway, S. J., et al. (2012) · MedChemComm · doi:10.1039/c2md20189e · Cited by 68
Self-citationGerona‐Navarro, G., Yoel-Rodríguez, Mujtaba, S., Frasca, A., Patel, J. A., Zeng, L., Plotnikov, A. N., Osman, R., & Zhou, M. (2011) · Journal of the American Chemical Society · doi:10.1021/ja107761h · Cited by 57
Li, J., Ghiani, C. A., Kim, J. Y., Liu, A., Sandoval, J., deVellis, J., & Casaccia‐Bonnefil, P. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0184-08.2008 · Cited by 53
p53-Induced Apoptosis and Inhibitors of p53
Nayak, S. K., Panesar, P. S., & Kumar, H. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709788681976 · Cited by 37
Tashiro, J., Kikuchi, S., Shinpo, K., Kishimoto, R., Tsuji, S., & Sasaki, H. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.21120 · Cited by 10
Cellular senescence and cancer
(1999) · doi:10.1002/(sici)1096-9896(199901)187:1
Cited by
Humphrey, P. A., Moch, H., Cubilla, A. L., Ulbright, T. M., & Reuter, V. E. (2016) · European Urology · doi:10.1016/j.eururo.2016.02.028 · Cited by 1,916
Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy
Biswas, S., & Rao, C. M. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.08.021 · Cited by 389
The role of fatty acid β-oxidation in lymphangiogenesis
Wong, B. W., Wang, X., Zecchin, A., Thienpont, B., Cornelissen, I., Kalucka, J., García-Caballero, M., Missiaen, R., Huang, H., Brüning, U., et al. (2017) · Nature · doi:10.1038/nature21028 · Cited by 336
Bromodomain inhibitors and cancer therapy: From structures to applications
Pérez-Salvia, M., & Esteller, M. (2017) · Epigenetics · doi:10.1080/15592294.2016.1265710 · Cited by 292
Zawistowski, J. S., Bevill, S. M., Goulet, D. R., Stuhlmiller, T. J., Beltran, A. S., Olivares-Quintero, J. F., Singh, D., Sciaky, N., Parker, J. S., Rashid, N. U., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0653 · Cited by 180
Metadata
- Authors
- Hay, D. A., Fedorov, O., Martin, S., Singleton, D. C., Tallant, C., Wells, C., Picaud, S., Philpott, M., Monteiro, O. P., Rogers, C. M., Conway, S. J., Rooney, T. P. C., Tumber, A., Yapp, C., Filippakopoulos, P., Bunnage, M. E., Müller, S., Knapp, S., Schofield, C. J., & Brennan, P. E.
- Venue
- Journal of the American Chemical Society
- Publisher
- American Chemical Society (ACS)
- Published
- 2014-06-19
- Volume
- 136
- Issue
- 26
- Pages
- 9308-9319
- ISSN
- 0002-7863 (ISSN-L)
- 1520-5126
- OpenAlex
- W1995827055
- Cited by
- 277
- References
- 62
- FWCI
- 13.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.